This article is more than 5 years old. Information may no longer be current.

VIDEO: Pembrolizumab benefits patients with HER-2–negative breast cancer

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO – The addition of pembrolizumab to standard chemotherapy improved the pathologic complete response rate among women with HER-2–negative breast cancer, according to results of the I-SPY 2 trial presented at the ASCO Annual Meeting.

Douglas Yee, MD, director of the Masonic Cancer Center, professor of medicine and pharmacology at University of Minnesota, and HemOnc Today Editorial Board member, describes the trial design and the impact of the results.

“All the HER-2–negative subgroups benefited from the addition of pembrolizumab,” including patients with hormone-receptor–positive and hormone-receptor–negative disease, Yee told HemOnc Today. “To the best of our knowledge, this is the first demonstration that you can add an agent to conventional cytotoxic chemotherapy in the hormone-receptor–positive subgroup and improve responses. That was very exciting.”